載入...
Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection
Ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin (OBV/PTV/r ± DSV ± RBV) is a new direct-acting antiviral (DAA) regimen which has improved efficacy of chronic hepatitis C virus (HCV) treatment significantly. OBV/PTV/r ± DSV ± RBV in clinical trials de...
Na minha lista:
| 發表在: | Clin Exp Hepatol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Termedia Publishing House
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5497406/ https://ncbi.nlm.nih.gov/pubmed/28856270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/ceh.2016.60247 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|